These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38660838)

  • 21. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Deremer DL; Ustun C; Natarajan K
    Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
    Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
    Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
    J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
    Huang X; Jiang Q; Hu J; Li J; Jin J; Meng F; Shen Z; Liu T; Wu D; Wang J; Wang J
    Front Med; 2019 Jun; 13(3):344-353. PubMed ID: 30159669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
    Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
    Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
    [No Abstract]   [Full Text] [Related]  

  • 29. [Advances in basic and clinical research of flumatinib].
    Jiang L; Yang MZ
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jun; 45(6):621-624. PubMed ID: 39134501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
    Henk HJ; Woloj M; Shapiro M; Whiteley J
    Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
    Eghtedar A; Kantarjian H; Jabbour E; O'Brien S; Burton E; Garcia-Manero G; Verstovsek S; Ravandi F; Borthakur G; Konopleva M; Quintas-Cardama A; Cortes J
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):477-84. PubMed ID: 23770156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
    Wang R; Cong Y; Li C; Zhang C; Lin H
    Medicine (Baltimore); 2019 Apr; 98(15):e15222. PubMed ID: 30985724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
    Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
    Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
    Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
    Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
    Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
    J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
    Whiteley J; Iyer S; Candrilli SD; Kaye JA
    Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.
    Bettiol A; Marconi E; Lombardi N; Crescioli G; Gherlinzoni F; Walley T; Vannacci A; Chinellato A; Giusti P
    Clin Drug Investig; 2018 Sep; 38(9):837-844. PubMed ID: 30043130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
    Cerrano M; Crisà E; Pregno P; Aguzzi C; Riccomagno P; Boccadoro M; Ferrero D
    Am J Hematol; 2013 Oct; 88(10):838-42. PubMed ID: 23757199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.